Taxotere Lawsuit

Leads For Personal Injury Law Firms

Although cancer is the second leading cause of death in this country, there are more than 15 million cancer survivors currently living here in the United States. While numerous cancer treatment options are available, they can be painful and draining, leaving people transformed in multiple ways. Many people can go on to live normal and healthy lives after battling cancer. However, a growing number of patients are experiencing permanent changes as a result of a chemotherapy drug called Taxotere.

Broughton Partners provides a legal case generation service that helps personal injury attorneys find patients who have become victims of Taxotere side effects. We deliver pre-qualified leads with retained Taxotere plaintiffs. The Taxotere leads your law firm receives are qualified retainers who have been fully reviewed for lawsuit eligibility. If your law firm is looking to help more patients who have suffered permanent hair loss due to Taxotere, call Broughton Partners today and connect with Taxotere plaintiffs.

What is Taxotere?

Taxotere is a chemotherapy drug that interferes with a cancer cell’s most basic functions.

Sometimes known as docetaxel, Taxotere is injected into a vein using an IV once every three weeks to inhibit a cell’s mitosis function. By interfering with cell division and replication, Taxotere helps to control and stop the spread of cancerous cells.

The drug was first approved by the U.S. Food and Drug Administration in 1999 for the treatment of non-small cell lung cancer and for prostate cancer and breast cancer treatment in 2004. The drug also received approval for use in the treatment of stomach, head, and neck cancers in 2006. It is manufactured and marketed by Sanofi-Aventis.

Taxotere is currently one of the most popular breast cancer drugs on the market but is also used for cancer of the lung, stomach, head, neck, and prostate.

Taxotere Linked to Permanent Hair Loss

Severe Taxotere Side Effects

  • Alopecia
  • Acute myeloid leukemia
  • Blood disorders
  • Skin reactions
  • Neurologic symptoms
  • Vision problems
  • Intoxication

Taxotere Lawsuit Claims

Claims against pharmaceutical companies include:

  • Failure to provide proper warnings about Taxotere’s side effects
  • Was aware of permanent hair loss side effects but continued to sell and market Taxotere
  • Failure to properly test Taxotere for potential risks
  • Negligent in the design, manufacturing, and marketing of Taxotere
  • Knowingly sold defective and dangerous drugs
  • Did not uphold their duty to create an unreasonably harmful product when used as intended
  • Caused permanent hair loss and alopecia among patients

Who is Eligible for a Lawsuit

  • Patients who have taken Taxotere as part of a chemotherapy regimen
  • Patients who have developed permanent alopecia that was diagnosed by a physician
  • Patients who clearly have apparent losses as a result of permanent hair loss

Taxotere Lawsuit

Cancer survivors claim that Taxotere caused permanent and unexpected hair loss.
The life-altering symptoms of alopecia led thousands of breast cancer survivors and their families to file lawsuits against Sanofi-Aventis, claiming that the manufacturer knew the drug could cause alopecia but failed to warn healthcare professionals or patients of the risk. Patients have also accused Sanofi-Aventis of false marketing.

October 2016

Taxotere lawsuits from 16 districts were consolidated into multidistrict litigation in the Eastern District of Louisiana.

September 2017

The court denied Sanofi-Aventis’ motion to dismiss the lawsuits.

August 2018

The New Jersey Supreme Court consolidated 353 Taxotere lawsuits into multicounty litigation.

March 2019

U.S. District Judge Jane Triche Milazzo postponed the first bellwether Taxotere trial to September 16, 2019.

References

Drugs.com. “Taxotere”, Drugs.com. Accessed April 9, 2018.

Sanofi. “Taxotere Prescribing Information”, Sanofi.us. Accessed April 9, 2018.

Palamaras, Loulios MD; Misciali, Cosimo MD; Vincenzi, Colombina MD; Robles, Wanda S. MD, PhD; Tosti, Antonella MD. “Permanent chemotherapy-induced alopecia: A review”, Journal of the American Academy of Dematology. Accessed April 9, 2018.

Kluger, N.; Jacot, W.; Frouin, E.; Rigau, V.;l Poujol, S.; Dereure, O.; Guillot, B.; Romieu, G. Bessis, D. “Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients”, Annals of Oncology. Accessed April 9, 2018.

American Cancer Society. “Find Support Programs and Services in Your Area”, American Cancer Society. Accessed April 9, 2018.

Menu